What changed from existing technology?
This study found that CRIF1 helps endometrial cancer cells grow and spread, and makes them less likely to die when treated with the drug paclitaxel.
This is the first study to show that CRIF1 is involved in paclitaxel resistance and aggressive behavior in endometrial cancer cells.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
common gynecological malignancy, and chemoresistance remains a major challenge in advanced-stage diseases. CR6-interacting factor 1 (CRIF1) has been imp
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Early research
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
CRIF1 could be a potential therapeutic target for improving paclitaxel sensitivity in endometrial cancer patients.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.